MLICM
MCRB icon

Metropolitan Life Insurance Company (MetLife)’s Seres Therapeutics MCRB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-267
Closed -$12.7K – 2373
2023
Q3 		$12.7K Hold
267
– – ﹤0.01% 2107
2023
Q2 		$25.5K Buy
267
+75
+39% +$8.16K ﹤0.01% 1798
2023
Q1 		$21.8K Sell
192
-21
-10% -$2.27K ﹤0.01% 1845
2022
Q4 		$23.9K Hold
213
– – ﹤0.01% 1912
2022
Q3 		$27.4K Buy
213
+142
+200% +$14.5K ﹤0.01% 1846
2022
Q2 		$4.88K Sell
71
-162
-70% -$14K ﹤0.01% 2340
2022
Q1 		$33.2K Sell
233
-458
-66% -$70.4K ﹤0.01% 1828
2021
Q4 		$115K Buy
691
+193
+39% +$30.7K ﹤0.01% 2391
2021
Q3 		$69.3K Sell
498
-477
-49% -$93.3K ﹤0.01% 2705
2021
Q2 		$465K Buy
975
+232
+31% +$97.9K 0.01% 1565
2021
Q1 		$306K Sell
743
-39
-5% -$18K ﹤0.01% 1730
2020
Q4 		$383K Hold
782
– – 0.01% 1540
2020
Q3 		$443K Sell
782
-5
-0.6% -$1.66K 0.01% 1297
2020
Q2 		$75K Buy
+787
New +$69K ﹤0.01% 2411
2017
Q4 		– Sell
-782
Closed -$251K – 2517
2017
Q3 		$251K Hold
782
– – ﹤0.01% 2150
2017
Q2 		$177K Buy
+782
New +$161K ﹤0.01% 2410
2016
Q4 		– Sell
-685
Closed -$168K – 2638
2016
Q3 		$168K Buy
685
+7
+1% +$2.46K ﹤0.01% 2444
2016
Q2 		$394K Buy
678
+355
+110% +$208K ﹤0.01% 1850
2016
Q1 		$172K Hold
323
– – ﹤0.01% 2259
2015
Q4 		$227K Buy
+323
New +$212K ﹤0.01% 2167

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MCRB Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 267 shares — an estimated $12.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MCRB in Q4 2015 and held it in 20 quarters. The position peaked at $465K in Q2 2021. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 267 Seres Therapeutics shares in Q4 2023, an estimated $12.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Seres Therapeutics in Q4 2015 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Seres Therapeutics position peaked at $465K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.